IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1028
Positioning
Market Dominance
Manufacturing
Medical Equipment
$3.8B
Waleed H. Hassanein
TransMedics Group, Inc. engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system. OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = TMDX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TMDX TransMedics Group, Inc. | 57 | 65 | 60 | 63 | 51.5x | 50.3x | 25.1% | 9.4% | 59.4% | 15.5% | 15.2% | 25.8% | 0.0% | 166.0x | $3.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
TransMedics Group, Inc. (TMDX) receives a "Hold" rating with a composite score of 57.0/100. It ranks #1028 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for TMDX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 65 | 73 | -8DRAG |
| MOMENTUM | 63 | 65 | -2NEUTRAL |
| VALUATION | 60 | 53 | +7ALPHA |
| INVESTMENT | 39 | 72 | -33DRAG |
| STABILITY | 65 | 63 | +2NEUTRAL |
| SHORT INT | 18 | 3 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 51.2% vs WACC 8.8% (spread +42.4%)
GM 59% vs sector 44%, OM 16% vs sector 3%
Capital turnover 3.16x, R&D intensity 10.9%
Rev growth 26%, 6yr history
Interest coverage 6.7x, Net debt/EBITDA 2.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate TransMedics Group, Inc. (TMDX) as a Hold with a composite score of 57.0/100 at a current price of $147.50. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
TransMedics Group, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.0/100 places it at rank #1028 in our full universe.
The near-term outlook is constructive, with revenue growing at 26% and momentum in the 63th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Wide
Medium
Standard
Undervalued
Gross margins of 59% signal strong pricing power.
Returns on equity of 25.1% exceed cost of capital.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 51.5x leaves little room for execution misses.
Leverage of 166% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
TransMedics Group, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns TransMedics Group, Inc. a Hold rating, with a composite score of 57.0/100 and 3 out of 5 stars. Ranked #1028 of 7,333 stocks, TMDX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
TMDX earns a quality score of 65/100, indicating above-average business quality. The company reports a return on equity of 25.1% (sector avg: -1.9%), gross margins of 59.4% (sector avg: 44.1%), net margins of 15.2% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
TMDX's value score of 60/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 51.48x, an EV/EBITDA of 50.29x, a P/B ratio of 12.92x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
TransMedics Group, Inc.'s investment score of 39/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 25.8% vs. a sector average of 6.7% and a return on assets of 9.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TMDX demonstrates moderate momentum with a score of 63/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 25.8% year-over-year, while a beta of 1.15 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
TMDX shows good financial stability with a score of 65/100. Key stability metrics include a beta of 1.15 and a debt-to-equity ratio of 166.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
TransMedics Group, Inc.'s short interest score of 18/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 166.00x). At $3.8B (mid-cap), TMDX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
TransMedics Group, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1028 of 7,333 overall (86th percentile). Key comparisons include ROE of 25.1% exceeding the -1.9% sector median and operating margins of 15.5% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TMDX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (65) vs Short Int. (18) — closing this gap could shift the rating.
EV/EBITDA 339% ABOVE SECTOR MEDIAN
ROE 1421% BELOW SECTOR MEDIAN
Gross Margin 35% ABOVE SECTOR MEDIAN (FAVORABLE)
About TransMedics Group TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System inc
Envestnet Asset Management Inc. significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 78.9% in Q3, now owning 47,048 shares valued at approximately $5.28 million. The company has a "Moderate Buy" consensus rating from equity analysts with a target price of $144.25, and institutional investors hold 99.67% of the stock. Despite insider selling of 8,920 shares over the past 90 days, TransMedics Group, a medical device company specializing in organ preservation, shows strong institutional confidence and positive analyst outlook.
TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $144.25. Analysts have recently raised price targets, indicating bullish sentiment, while institutional investors hold nearly all of the stock. Insider selling occurred last quarter, totaling approximately $1.26 million.
TransMedics Group, Inc. (TMDX) is a strong player in the medical device sector with a $4.44 billion market cap and innovative Organ Care System. Analysts are predominantly positive on TMDX, with an average target price suggesting an 11.06% upside, driven by impressive revenue growth and strategic reinvestment of earnings. Despite neutral short-term technical indicators, the company's focus on expansion and innovation in organ transplant therapy presents a promising opportunity for growth-oriented investors.
TransMedics Group Inc (NASDAQ:TMDX) has been identified as a high-momentum growth stock based on Louis Navellier’s "The Little Book That Makes You Rich" strategy. The company demonstrates strong financial performance, including positive earnings revisions and surprises, accelerating revenue and EPS growth, widening profit margins, strong cash flow, and high return on equity. While traditional valuation metrics appear costly, its impressive growth rate makes its valuation more acceptable relative to peers.
Above 50MA
37.18%
Net New Highs
+51081